Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$4.68 USD

4.68
213,764

+0.02 (0.43%)

Updated Oct 16, 2024 04:00 PM ET

After-Market: $4.68 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

What's in the Cards for Arena (ARNA) This Earnings Season?

Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q3.

    Is a Beat in the Cards for ImmunoGen (IMGN) in Q3 Earnings?

    ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the company's third-quarter results.

      Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

      Zoetis' (ZTS) top line is expected to be driven by newly launched Apoquel, Simparica and Cytopoint. The approvals of Clavamox and Nexvet are expected to boost sales further.

        Is a Turnaround in Store for Teva (TEVA) in Q3 Earnings?

        Teva's (TEVA) generic segment may continue to see weakness due to significant competitive and pricing pressure in the U.S. generics industry, which will continue to hurt the top line.

          What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?

          Immune Design (IMDZ) will remain focused on the development of its key pipeline candidate's CMB305 and G100 in the third quarter of 2017.

            What's in the Offing for Intercept (ICPT) in Q3 Earnings?

            Intercept Pharmaceuticals, Inc. (ICPT) is likely to see a dip in Ocaliva sales when it reports third-quarter results on Nov 1.

              Alkermes (ALKS) Beats Q3 Earnings Estimates, Cuts Sales View

              Alkermes' (ALKS) earnings beat estimates but sales lagged the same in the third quarter of 2017.

                Sarepta (SRPT) Q3 Loss Narrows, Exondys 51 Sales View Raised

                Sarepta (SRPT) beat estimates on both counts in the third quarter of 2017 on strong sales of Exondys 51. Sarepta's pipeline candidate, golodirsen, shows potential.

                  Is a Beat in Store for Agenus (AGEN) This Earnings Season?

                  Agenus (AGEN) is expected to report third-quarter 2017 on Oct 26.

                    Agenus (AGEN) Remains Focused on Drug Development Programs

                    Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.

                      Why Is Agenus (AGEN) Down 11.8% Since the Last Earnings Report?

                      Agenus (AGEN) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag

                        Agenus Inc. (AGEN) witnesses narrower-than-expected loss and also misses revenue estimates. However, the company is progressing well with the candidates in its pipeline in Q2.

                          Agenus (AGEN) Reports Narrower-than-Expected Q2 Loss

                          Agenus reported narrower-than-expected loss in the second quarter of 2017 but revenues missed expectations.

                            Sucampo (SCMP) Q2 Earnings & Revenues Beat Estimates, Up Y/Y

                            Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in Japan, which drove the company's top line. The company is also working on expanding its pipeline and Amitizia's label.

                              Exact Sciences Corporation (EXAS) Jumps: Stock Rises 6.2%

                              Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 6% on the day after the company delivered yet another quarter of greater than 100% top-line growth.

                                What's in Store for Endocyte (ECYT) this Earnings Season?

                                Endocyte (ECYT) looks forward to shift its focus on CAR T-cell small-molecule drug conjugates (SMDCs) adaptor platform, the dual-targeted DNA crosslinker drug EC2629 in Q2.

                                  Tirthankar Chakraborty headshot

                                  New Strong Buy Stocks for July 26th

                                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

                                    What to Expect from International Paper (IP) in Q2 Earnings?

                                    Fluctuations in actual equity market returns, changes in general interest rates are likely to hurt International Paper (IP) in Q2 earnings.

                                      S&P Global (SPGI) to Post Q2 Earnings: A Beat in the Cards?

                                      S&P Global's (SPGI) strategic portfolio restructuring and focus on core business are expected to have a positive impact on the company's second-quarter results.

                                        VASCO (VDSI) to Report Q2 Earnings: What's in the Offing?

                                        Vasco's (VDSI) focus on generating high operating margins, backed by continuous investments and a shift in the product mix with higher gross-margin products, is likely to boost its Q2 earnings.

                                          Is a Beat in Store for Agenus (AGEN) this Earnings Season?

                                          Agenus Inc. (AGEN) will focus on the development of all its pipeline drugs as currently there are no marketed drug in its portfolio.

                                            What to Expect from Keryx (KERX) this Earnings Season?

                                            Keryx Biopharmaceuticals, Inc. (KERX) intends to focus on the growth of Auryxia in the U.S. dialysis market. The company is also making efforts for label expansion on Auryxia in the iron-deficiency anemia (IDA) indication.

                                              Is a Beat in Store for Alexion (ALXN) this Earnings Season?

                                              Alexion Pharmaceuticals, Inc.'s (ALXN) drugs like Soliris and Strensiq have been performing well. Let's see if these lead the company to an earnings beat.

                                                uniQure N.V. (QURE) Shows Strength: Stock Moves 9.1% Higher

                                                uniQure N.V. (QURE) was a big mover last session, as the company saw its shares rise a little above 9% on the day.

                                                  Tirthankar Chakraborty headshot

                                                  New Strong Buy Stocks for July 20th

                                                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday